GSK’s global HIV business, ViiV Healthcare, has signed two separate transactions, which are expected to complete independently during the first half of next year.
The deals are subject to required approvals, anti-trust and regulatory clearances.
ViiV Healthcare will pay $350m to acquire BMS’ late stage pipeline of HIV medicines, as well as its pre-clinical and discovery phase assets.
The first transaction includes fostemsavir attachment inhibitor, which is currently in phase III development for heavily treatment experienced patients, and a maturation inhibitor that is in phase IIb development for both treatment-naive and treatment experienced patients.
A back-up maturation inhibitor candidate is also included in the acquisition.
Assets in preclinical and discovery phases of development include a novel biologic with a triple mechanism of action, a further maturation inhibitor, an allosteric integrase inhibitor and a capsid inhibitor.
BMS will get potential development and regulatory milestone payments of about $518m for the clinical assets and around $587m for the discovery and pre-clinical programs.
ViiV Healthcare will pay tiered royalties after approval and commercialization of the products.
The company will also pay sales-based milestone payments of about $750m for each of the clinical assets and up to $700m for discovery and pre-clinical programs
GSK chief strategy officer and ViiV Healthcare chairman David Redfern said: "These acquisitions strengthen our leadership and innovation in HIV, one of our core areas of scientific research at GSK.
"The addition of two potential first-in-class late-stage treatments and several promising early clinical development programmes strengthens ViiV Healthcare’s pipeline and provides us with further new opportunities for growth."
Image: GlaxoSmithKline headquaters in Brentford, London, England. Photo: courtesy of Maxwell Hamilton.